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Abstract: Diabetes and frailty are highly prevalent conditions that impact the health status of
older adults. Perturbations in protein/amino acid metabolism are associated with both functional
impairment and type 2 diabetes mellitus (T2DM). In the present study, we compared the concentrations
of a panel of circulating 37 amino acids and derivatives between frail/pre-frail older adults with
T2DM and robust non-diabetic controls. Sixty-six functionally impaired older persons aged 70+ with
T2DM and 30 age and sex-matched controls were included in the analysis. We applied a partial least
squares-discriminant analysis (PLS-DA)-based analytical strategy to characterize the metabotype of
study participants. The optimal complexity of the PLS-DA model was found to be two latent variables.
The proportion of correct classification was 94.1 ± 1.9% for frail/pre-frail persons with T2DM and 100%
for control participants. Functionally impaired older persons with T2DM showed higher levels of
3-methyl histidine, alanine, arginine, glutamic acid, ethanolamine sarcosine, and tryptophan. Control
participants had higher levels of ornithine and taurine. These findings indicate that a specific profile
of amino acids and derivatives characterizes pre-frail/frail older persons with T2DM. The dissection of
these pathways may provide novel insights into the metabolic perturbations involved in the disabling
cascade in older persons with T2DM.
Keywords: aging; metabolomics; systems biology; personalized medicine; metabolism; frailty;
sarcopenia; muscle wasting; precision medicine; metabolic profiling
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1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic condition frequently occurring in old age [1,2].
T2DM is associated with higher risk of negative outcomes, including disability and mortality [3].
T2DM-related complications are especially prevalent in older adults and account for the increasing
costs of T2DM [4]. Frailty defines a geriatric syndrome characterized by reduced ability to cope
with life stressors and increased risk of adverse events (e.g., falls, delirium, loss of independence,
mortality) [5,6]. T2DM and frailty are intimately related and share common features, including complex
pathophysiology and heterogeneous phenotypes [7], that challenge their management [5,8].
Muscle failure, both in its metabolic and functional manifestations, is a hallmark of T2DM
and frailty [7,9]. The progressive and generalized loss of muscle mass, strength, and function with
age, termed sarcopenia, fuels a self-reinforcing cycle in which structural, metabolic, and endocrine
perturbations in muscle exacerbate T2DM-related signs and symptoms [10]. T2DM further promotes
the decline in muscle mass and function [11,12] which, in turn, aggravates functional impairment [13].
The central role of muscle wasting in frailty and T2DM may guide the identification of novel
biomarkers and possibly new treatment targets for the two conditions [14–16]. In this context,
circulating amino acids are promising candidates given their sensor-transducer-effector role in systemic
metabolism, muscle homeostasis, and physical function [17–20]. Moreover, amino acids are involved
in processes critical to the development and progression of frailty and T2DM, such as inflammation,
glucose homeostasis, and redox regulation [21–23].
Targeted metabolomics allowed identifying specific amino acid profiles that were associated
with insulin resistance and risk of developing T2DM in independent cohorts across US, Europe,
and China [24–27]. A plasma amino acid signature, together with specific circulating lipid species,
was linked to glucose dyshomeostasis and impaired insulin sensitivity in older adults from the
Baltimore Longitudinal Study of Aging (BLSA) [28]. In addition, distinct patterns of circulating amino
acids were associated with frailty and/or muscle-related parameters (mass, turnover, performance) in
older individuals at risk for frailty [29–32]. Finally, within the “BIOmarkers associated with Sarcopenia
and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study, a combination of serum amino acids
and derivatives was identified that characterized the metabotype of older adults with physical frailty
and sarcopenia (PF&S) [17].
Here, we sought to define the circulating amino acid profile of frail/pre-frail older adults with
T2DM (F-T2DM). Our approach, described in the context of the “Metabolic biomarkers of frailty
in older people with type 2 diabetes mellitus” (MetaboFrail) study, coupled targeted metabolomics
with a chemometric modeling strategy [16]. Through this innovative biomarker discovery strategy,
we identified a specific profile of serum amino acids in F-T2DM older people. These findings may offer
new insights into the metabolic perturbations associated with the disabling cascade in older persons
with T2DM.
2. Materials and Methods
2.1. Study Population
MetaboFrail was developed as an ancillary study of the “Multi-modal Intervention in Diabetes in
Frailty” (MID-Frail) project [16,33,34]. The latter was a cluster-randomized multicenter clinical trial that
evaluated the effectiveness of a multicomponent intervention (mainly based on resistance exercise and
lifestyle counseling) on improving physical performance compared with usual care in F-T2DM older
adults from seven European countries (ClinicalTrials.gov identifier: NCT01654341) [16,33]. For the
present study, a subgroup of MID-Frail participants recruited in Spanish and French study centers were
enrolled. The main eligibility criteria were: (a) age at screening 70 years or older; (b) T2DM diagnosis
from at least two years; and (c) being pre-frail or frail according to Fried’s criteria [35]. The main
exclusion criteria were: (a) poor cognition operationalized as a Mini Mental State Examination score
<20 [36]; (b) severe disability defined as a Barthel index score <60 [37]; critical conditions and/or major
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illnesses with a life expectancy <6 months; (c) inability or unwillingness to provide informed consent.
Control participants were enrolled at the Università Cattolica del Sacro Cuore (Rome, Italy) and had
the following characteristics: 70+ years of age, no T2DM, and no functional impairment. The study
protocol was approved by local ethics committees according to both national and international laws.
Prior to enrolment, all participants provided written informed consent. The study was conducted in
agreement with legal requirements and international norms (Declaration of Helsinki, 1964).
2.2. Blood Collection and Determination of Serum Concentrations of Amino Acids and Derivatives
Blood samples were collected after overnight fasting. For serum separation, blood samples were
kept on ice for about 30 min until clotting and were subsequently centrifuged at 1000× g for 10 min at
4 ◦C. Serum samples were eventually aliquoted and stored at −80 ◦C until analysis.
Concentrations of 37 amino acids and derivatives were determined in serum by ultraperformance
liquid chromatography/mass spectrometry (UPLC/MS), as described previously [17]. Briefly, 50 µL of
sample was added to 100 µL 10% (w/v) sulfosalicylic acid containing an internal standard mix (50 µM;
Cambridge Isotope Laboratories, Inc., Tewksbury, MA, USA) and centrifuged at 1000× g for 15 min.
Ten µL of the resulting supernatant were mixed with 70 µL of borate buffer and 20 µL of AccQ Tag
reagents (Waters Corporation, Milford, MA, USA) and heated at 55 ◦C for 10 min. Samples were
eventually loaded onto a CORTECS UPLC C18 column 1.6 µm 2.1 × 150 mm (Waters Corporation) for
chromatographic separation (ACQUITY H-Class, Waters Corporation, Milford, MA, USA). Elution was
performed at 500 µL/min flow rate with a linear gradient (9 min) from 99:1 to 1:99 water 0.1% formic
acid/acetonitrile 0.1% formic acid. Analytes were detected on an ACQUITY QDa single quadrupole
mass spectrometer equipped with electrospray source operating in positive mode (Waters Corporation,
Milford, MA, USA). Amino acid controls (MCA laboratory of the Queen Beatrix Hospital, Winterswijk,
The Netherlands) were used to monitor the analytic process.
2.3. Statistical Analysis
The normal distribution of data was ascertained through the Kolmogorov-Smirnov test.
Comparisons between F-T2DM and control participants for normally distributed continuous variables
were performed by t-test statistics. The non-parametric test Mann-Whitney U was applied to assess
differences for non-normally distributed continuous data. Differences in categorical variables between
groups were determined via χ2 statistics. Descriptive analyses were performed using the GraphPrism
5.03 software (GraphPad Software, Inc., San Diego, CA), with statistical significance set at p < 0.05.
2.4. Partial Least Squares-Discriminant Analysis and Double Cross-Validation Procedures
In order to unveil possible differences in circulating amino acid patterns between F-T2DM and
control participants, a multivariate classification strategy based on partial least squares-discriminant
analysis (PLS-DA) modeling was adopted [38]. PLS-DA is a classification method particularly suited for
dealing with highly correlated predictors, as it is based on projecting the predictors (measured variables)
onto a reduced subspace of latent variables (LVs; directions in space) of highest covariance with
the responses, i.e., providing the maximum separation between classes. In order to validate the
results of PLS-DA modeling and rule out the possibility that good results were obtained because of
chance correlation, a procedure based on repeated double cross-validation (DCV) and permutation
tests was used [39,40]. DCV consists of spitting the samples to obtain two cross-validation loops,
an internal loop for model building/model selection and an outer loop that mimics external (test set)
validation. The DCV procedure is repeated a sufficient number of times such that estimates do to
depend on one specific sample splitting. This allows evaluating the consistency of model parameters
and the confidence intervals for model predictions. To assess the statistical significance of the
obtained predictions, the figures of merit which summarize the classification accuracy in repeated
DCV [i.e., number of misclassifications (NMC), area under the receiver operating characteristic curve
(AUROC), and discriminant (DQ2)] are compared with their distribution under the null hypothesis,
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which is estimated non-parametrically through permutation tests with 1000 randomizations. A more
detailed description of the procedure can be found elsewhere [41]. PLS-DA and DCV were run
under Matlab R2015b environment by means of in-house written functions (freely downloadable at:
https://www.chem.uniroma1.it/romechemometrics/research/algorithms/plsda/).
3. Results
3.1. Study Population
The present investigation included 66 F-T2DM older adults and 30 age and sex-matched robust,
non-diabetic controls. The main characteristics of the two groups are reported in Table 1. F-T2DM
and control participants were comparable for age, sex distribution, and number of diseases. F-T2DM
older adults showed higher body mass index relative to controls. As expected, a significant difference
was found in physical functional between groups, as indicated by the scores on the short physical
performance battery (SPPB).
Table 1. Main characteristics of study participants.
F-T2DM (n = 66) Controls (n = 30) p
Age, years (mean ± SD) 76.5 ± 14.5 74.6 ± 4.3 0.46
Sex (female), n (%) 32 (48) 16 (53) 0.82
BMI, kg/m2 (mean ± SD) 29.2 ± 4.9 26.7 ± 2.4 0.01
SPPB score (mean ± SD) 8.6 ± 2.9 11.3 ± 0.9 <0.0001
Number of diseases (mean ± SD) § 2.8 ± 1.0 2.9 ± 2.0 0.86
§ Includes hypertension, coronary artery disease, prior stroke, peripheral vascular disease, diabetes, chronic
obstructive pulmonary disease, and osteoarthritis; Abbreviations: BMI, body mass index; F-T2DM, frail/pre-frail
older adults with type 2 diabetes mellitus; SD, standard deviation; SPPB, short physical performance battery.
3.2. Identification of Circulating Amino Acid Profiles
In the present study, we aimed at identifying profiles of circulating amino acids that discriminate
older persons with F-T2DM from functionally intact non-diabetic peers. Among the available statistical
options, we selected a PLS-DA-based strategy for its ability to handle multiple interdependent
variables. The best PLS-DA model was built using two LVs. As indicated by the stringent DCV
applied, the classification performance of the model was almost perfect. Indeed, the proportion of
correct classification of participants was 96.6 ± 1.5% over the calibration sets (95.0 ± 2.2% for cases
and 100.0 ± 0.0% for controls), 96.6 ± 1.5% (95.0 ± 2.2% for cases and 100.0 ± 0.0% for controls) in
the internal DCV loop (i.e., the one used for model selection), and 95.9 ± 1.3% (94.1 ± 1.9% for cases
and 100.0 ± 0.0% for controls) in the outer DCV loop, which accounts for the results of repeated
external validation.
The remarkable classification performance of the PLS-DA model can be appreciated by inspecting
the projection of study participants over the space spanned by the two LVs (Figure 1).
A sharp separation between F-T2DM participants and controls is evident. To ensure the reliability
of our findings against the possibility of chance correlations, DCV results of the PLS-DA model were
compared with the distributions of specific figures of merit under the null hypothesis. As depicted
in Figure 2, for all of the figures considered (i.e., NMC, AUROC, and DQ2), values obtained from
the unpermuted dataset fell outside the corresponding null hypothesis distribution, indicating a
p value <0.05.
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Figure 2. Distribution of values of number of misclassifications (N C), area under the receiver
operating characteristic curve (AUROC), and discriminant Q2 (DQ2) under their respective null
hypothesis as estimated by permutation tests (blue histograms) and the corresponding values obtained
by the partial least squares-discriminant analysis model on unpermuted data (red circles). Values
obtained on the real dataset (red circles) fall outside of the corresponding null hypothesis distribution
(blue histograms), corresponding to a p < 0.05.
The identification of the metabolites with the greatest discriminating power was accomplished by
inspecting variable importance in projection (VIP) indices. Table 2 reports variables with a VIP value
higher than 1.
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Table 2. Serum concentrations of discriminant biomolecules as resulted from partial least
squares-discriminant analysis.
Analytes F-T2DM (n = 66) Controls (n = 30)
3-methylhistidine 7.8 ± 4.2 5.2 ± 2.5
Alanine 542.3 ± 165.8 384.3 ± 98.3
Arginine 168.3 ± 91.2 103.7 ± 31.2
Ethanolamine 11.5 ± 3.4 9.0 ± 2.2
Glutamic acid 130.0 ± 66.8 54.3 ± 21.3
Ornithine 103.2 ± 37.6 109.4 ± 25.0
Sarcosine 2.5 ± 0.9 1.6 ± 0.6
Taurine 100.4 ± 49.0 189.5 ± 47.2
Tryptophan 66.2 ± 23.4 62.0 ± 13.1
Data are shown as mean ± standard deviation. Concentrations are expressed in µmol/L.
F-T2DM participants showed higher serum levels of 3-methyl histidine, alanine, arginine,
ethanolamine, glutamic acid, sarcosine, and tryptophan. Instead, controls were characterized by higher
circulating levels of ornithine and taurine. Serum concentrations of non-discriminant analytes in the
two participant groups are listed in Table S1.
4. Discussion
Over the last few years, analytical platforms have been developed together with sophisticated
computational algorithms to allow the study of complex diseases in unprecedented detail [42]. This new
healthcare paradigm, called personalized or precision medicine, incorporates “omics” technologies
to unveil the inner biological properties of morbid conditions [42] and devise innovative diagnostics
and interventions tailored to the needs of single individuals [42,43]. Metabolomics, by virtue of
its privileged position at the interface between biological pathways and clinical manifestations of
healthy/disease conditions [44], are improving our understanding of “normal” physiology and the
pathophysiology of many disorders, including frailty and T2DM [15,45,46]. These premises led to the
design of the MetaboFrail study [16].
In the present investigation, we applied targeted metabolomics to characterize the circulating
amino acid profile of functionally impaired older persons with T2DM. Our major finding was that
a specific pattern of amino acids discriminated F-T2DM older people from age- and sex-matched
controls. The amino acid signature of F-T2DM participants included higher circulating levels of
3-methyl histidine, alanine, arginine, ethanolamine, glutamic acid, sarcosine, and tryptophan.
The presence of 3-methyl histidine among the most relevant predictors supports the involvement
of muscle wasting in frailty [30]. Indeed, 3-methyl histidine derives from the post-translational
methylation of histidine moieties of actin and myosin [47,48]. Hence, 3-methyl histidine has been
proposed as a biomarker of myofibrillar proteolysis and skeletal muscle loss [49]. Interestingly, 3-methyl
histidine is also a marker of increased protein catabolism in T2DM [50].
Alanine and glutamic acid are crucial intermediates of muscle energy metabolism and liver-muscle
metabolic interchange under both physiologic and pathologic conditions [51–53]. Perturbations in
alanine and glutamate circulating pool may be indicative of skeletal muscle dysfunction, and are
commonly encountered in age-related chronic conditions and models of muscle atrophy [54,55].
Notably, both alanine and glutamic acid levels were positively associated with insulin resistance and
risk of T2DM in several independent study cohorts [56–58].
Arginine metabolism involves the cooperation of various organs, including kidneys, muscles,
gut, and liver [59]. Major pathways in arginine metabolism include muscle protein breakdown and
its de novo synthesis from citrulline [59]. Arginine is involved in nitric oxide as well as urea and
polyamine synthesis, and research focus has recently been directed towards the determination of the
pathophysiological role of arginine and its metabolites in aging and age-related chronic diseases [60].
Noticeably, our findings mirror the higher levels of arginine and lower concentrations of its urea-cycle
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companion ornithine found in Chinese adults with T2DM [61]. Higher concentrations of another
intermediate of urea-cycle, i.e., citrulline, defined the serum amino acid profile of older people with
PF&S [17]. Further investigations on arginine/nitrogen interorgan networks are needed to explain the
results found in F-T2DM older adults.
Sarcosine, the N-methylated derivative of glycine, is an important intermediate of one-carbon
metabolism [62]. Recent studies have investigated the association between sarcosine levels and
age-related conditions in humans with conflicting results [63–66]. In a comparative metabolomics
analysis, circulating sarcosine was found to be reduced with aging and increased by dietary restriction
in both rodents and humans [67]. Conversely, elevated urine sarcosine levels were associated with
incident T2DM [68], and higher serum concentrations of sarcosine characterized the metabotype of
older adults with PF&S [17]. Collectively, these findings suggest that perturbations in folate/one-carbon
metabolism may play a role in frailty and T2DM as well as in other age-related conditions.
Ethanolamine is a crucial intermediate of the CDP-ethanolamine pathway, the main route
of phosphatidylethanolamine synthesis, and modulates lipid metabolism and the turnover of
biological membranes [69]. Recently, a critical role for skeletal muscle phospholipid metabolism
has been described in the regulation of both insulin sensitivity and contractile function [70].
Moreover, the ethanolamine/phosphatidylethanolamine synthesis dyad is directly involved in
autophagy regulation, thereby modulating anti-aging properties of this cellular process [71].
Interestingly, perturbations in the CDP-ethanolamine pathway were associated with altered
mitochondrial biogenesis in mouse models of muscle atrophy [71], while higher circulating levels of
ethanolamine were found in older adults with PF&S [17].
Tryptophan is an essential amino acid that exerts multiple roles in growth, mood, behavior,
and immune responses [72]. Tryptophan is metabolized via two major pathways, the
tryptophan-kynurenine and the tryptophan-methoxyndole pathways, that lead to the production of
NAD, serotonin, and melatonin [72]. Alterations in tryptophan metabolism have been described in
the context of frailty and T2DM [73,74]. In particular, tryptophan and its associated metabolites have
been associated with insulin resistance and incident T2DM in independent cohorts [74,75]. Moreover,
higher circulating levels of tryptophan were associated with low muscle quality in a large cohort of
men and women enrolled in the BLSA [32].
Non-frail non-T2DM controls were characterized by higher serum levels of taurine. Taurine is
the most abundant free amino acid in several organs, including the skeletal muscle that contains
approximately 70% of total body taurine [76]. Taurine has multiple regulatory effects and its role
in osmoregulation, modulation of inflammatory response, protection against oxidative stress, and
stimulation of cellular quality control processes is widely acknowledged [76,77]. Taurine deficiency is
commonly encountered in people with T2DM [78,79], and its supplementation has been proposed as a
strategy against T2DM complications, including retinopathy, nephropathy, neuropathy, atherosclerosis,
and cardiomyopathy [80]. Recently, taurine supplementation has also been proposed as a possible
remedy against sarcopenia [81]. The causes of taurine depletion in F-T2DM older adults are
multifaceted and may include decreased dietary intake, reduced intestinal absorption, renal wasting,
and inflammation [77].
Unexpectedly, branched-chain amino acids (BCAAs) were not found to be discriminant by the
PLS-DA classification model. BCAAs are metabolic rheostats that modulate whole-body and tissular
metabolism [20]. Recent evidence suggests that BCAAs may have a Janus-like behavior in F-T2DM
older adults. Indeed, while BCAA-induced activation of the mammalian target of rapamycin (mTOR) in
skeletal myocytes may contrast sarcopenia and functional decline in advanced age [20,31], other studies
found an association between higher circulating levels of BCAAs and insulin resistance or T2DM in
older adults [24–27]. The low discriminant power of BCAAs in MetaboFrail might therefore reflect the
dual effect of BCAAs in F-T2DM older people.
Although innovative, the present investigation has some limitations that should be mentioned.
The study sample was quite small while the dataset comprised numerous variables. To cope with
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this issue, we adopted a PLS-DA-based strategy which is particularly suited for handling matrices
populated by highly correlated variables. The MetaboFrail study enrolled older adults from three
European countries; thus, a validation study in other ethnic groups is warranted. Eating habits
may affect circulating amino acid levels, but diet was not objectively assessed in our study sample.
However, it has recently been reported that differences in blood amino acid concentrations do not
necessarily mirror those of amino acid intakes [82]. As commonly occurs in biomarker discovery
studies, although a large number of candidates were investigated, we could not evaluate all possible
mediators involved in frailty and T2DM.
In conclusion, in the present investigation, we showed the existence of a specific amino acid
signature in F-T2DM older persons. Our novel approach enabled us to obtain new insights into
the pathophysiology of the two conditions. In particular, a relevant role for perturbations in
muscle metabolism and muscle-liver interorgan communication was highlighted. The longitudinal
implementation of our analytical strategy could allow validating novel sets of biomarkers and
identifying new targets for interventions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/1/199/s1;
Table S1: Serum concentrations of non-discriminant amino acids and derivatives in frail/pre-frail participants with
type 2 diabetes mellitus (F-T2DM) and controls.
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